Soligenix Inc (OTCBB:SNGX) reported the publication of data showcasing a heat stable vaccine formulation of a HPV vaccine. The research was carried out at the University of Colorado, Boulder. The researchers showcased the conversion of a commercial VLP based vaccine that needs cold-chain storage to an alum-adjuvanted, subunit, vaccine which is constant at ambient temperatures.
The research work was supported by the SPORE in cervical cancer and University of Colorado Seed grant. It is the first display of the use of Soligenix’s ThermoVax™ technology for the advancement of a subunit commercial vaccine. The technology is licensed from the ‘University of Colorado.’
ThermoVax™ has been formerly shown to increase thermostability of both an anthrax vaccine and a ricin vaccine. It highlights stability of up to 12 months at 104 degrees Fahrenheit or 16 weeks at 158 degrees Fahrenheit. In this research, the new HPV vaccine was established to be stable for minimum 12 weeks at 122 degrees Fahrenheit, consistent with initial data. The findings were published in the European Journal of “Pharmaceutics and Biopharmaceutics.”
Soligenix has been formulating its heat stabilization technology, known as ThermoVax™, to be applied in numerous vaccine applications, including both infectious and biodefense disease. It is the first display of the compatibility of the advanced technology ThermoVax™ with commercial vaccine indications.
In former trials, vaccination with thermostabilized RiVax™, utilizing the technology, shielded all animals from severe death resulting from aerosolized ricin exposure. The unvaccinated animals died within forty hours. The neutralizing antibody profile matched the profile seen in samples from humans initially immunized with the RiVax™ vaccine.
In last trading session, the stock price of Soligenix Inc (OTCBB:SNGX) surged more than 9% to close the trading session at $1.66. The gains came at a share volume of 76,909 compared to average share volume of 71,181. The market cap stands at $43.20 million.